Short Interest in Nymox Pharmaceutical Corp (NASDAQ:NYMX) Increases By 8.0%

Nymox Pharmaceutical Corp (NASDAQ:NYMX) saw a large increase in short interest in May. As of May 31st, there was short interest totalling 1,660,200 shares, an increase of 8.0% from the April 30th total of 1,537,100 shares. Approximately 4.4% of the shares of the stock are short sold. Based on an average trading volume of 87,300 shares, the days-to-cover ratio is presently 19.0 days.

Shares of NYMX traded up $0.01 during mid-day trading on Friday, hitting $1.75. 68,652 shares of the company’s stock were exchanged, compared to its average volume of 290,069. Nymox Pharmaceutical has a fifty-two week low of $1.25 and a fifty-two week high of $3.47. The company has a debt-to-equity ratio of 0.03, a quick ratio of 8.01 and a current ratio of 8.04. The company has a 50-day moving average of $1.59.

Nymox Pharmaceutical (NASDAQ:NYMX) last issued its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter. The firm had revenue of $0.03 million during the quarter. Nymox Pharmaceutical had a negative net margin of 6,101.69% and a negative return on equity of 175.82%.

Large investors have recently modified their holdings of the stock. Northern Trust Corp lifted its holdings in Nymox Pharmaceutical by 2.2% in the fourth quarter. Northern Trust Corp now owns 277,557 shares of the biopharmaceutical company’s stock valued at $363,000 after acquiring an additional 6,026 shares during the period. Bank of America Corp DE lifted its holdings in Nymox Pharmaceutical by 130.1% in the fourth quarter. Bank of America Corp DE now owns 148,443 shares of the biopharmaceutical company’s stock valued at $195,000 after acquiring an additional 83,925 shares during the period. Geode Capital Management LLC lifted its holdings in Nymox Pharmaceutical by 10.8% in the fourth quarter. Geode Capital Management LLC now owns 134,021 shares of the biopharmaceutical company’s stock valued at $175,000 after acquiring an additional 13,103 shares during the period. Rhumbline Advisers lifted its holdings in Nymox Pharmaceutical by 44.9% in the fourth quarter. Rhumbline Advisers now owns 42,560 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 13,180 shares during the period. Finally, Private Advisor Group LLC acquired a new stake in Nymox Pharmaceutical in the fourth quarter valued at $49,000. 5.66% of the stock is currently owned by hedge funds and other institutional investors.

Nymox Pharmaceutical Company Profile

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease.

See Also: Limitations to arbitrage trading

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.